Menu
Facebook-f Twitter Linkedin-in Google
Search
Expert Opinion

Get A Second Opinion

The medical second opinion will be presented to you within 48 hours.
Home/Assoc. Prof. Tugba Akın Telli, M.D.
tuğba akın telli

Watch Doctor Video

Assoc. Prof. Tugba Akın Telli, M.D.

DEPARTMENT : Medical Oncology

PRIMARY LOCATION : Istanbul Florence Nightingale Hospital

LANGUAGES : English, German, Turkish

REQUEST A MEDICAL OPINION
Present
Istanbul Florence Nightingale Hospital
Medical Oncology
2022-2024
Memorial Şişli Hospital
Medical Oncology Specialist
2021-2022
Institut Jules Bordet
Clinical Research Fellowship
2020-2022
Marmara University Pendik Training and Research Hospital
Medical Oncology Specialist
2019-2019
Institut Jules Bordet
Clinical Research Fellowship
2016-2019
Marmara University Faculty of Medicine, Department of Medical Oncology
Medical Oncology Fellowship
2014-2016
Golbasi Public Hospital
Internal Medicine Specialist
2013-2014
MD Anderson Cancer Center
Observership
2013
Bellvitge Hospital, Barcelona, Spain
Observership
2009 -2014
Hacettepe University Faculty of Medicine
Internal Medicine Residency
  • Lip Cancer
  • Hematologic Cancers
  • Hodgkin’s Lymphoma
  • Gynecologic Tumors
  • Kaposi Sarcoma
  • Liver Cancer
  • Carcinoma
  • Colorectal Cancer (Large Bowel Cancer)
  • Lymphoma
  • Liposarcoma
  • Malignant Fibrous Histiocytoma
2008 – 2009
Akdeniz University, Faculty of Medicine
Internship
2007
Bilkent University Department of Molecular Biology and Genetics
Summer Internship
2003 – 2008
Akdeniz University, Faculty of Medicine
  1. Filizoglu N, Ozguven S, Akin Telli T, Ones T, Dede F, Turoglu HT, Erdil TY. Defining the optimal segmentation method for measuring somatostatin receptor expressing tumor volume on 68Ga-DOTATATE positron emission tomography/computed tomography to predict prognosis in patients with gastroenteropancreatic neuroendocrine tumors. Nucl Med Commun. 2024 May 15. doi: 10.1097/MNM.0000000000001861.
  2. Assaf I, Fimereli D, Anthoine G, Fazio R, Daprà V, Audisio A, Bardiaux A, Telli TA, Vanhooren M, Saude-Conde R, Bregni G, Hendlisz A, Sclafani F. Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer. Cancers (Basel). 2023 Dec 13;15(24):5823. 
  3. Arikan R, Akin Telli T, Isik S, Sari M, Kostek O, Ercelep O, et al. Evaluation of Clinicopathological Characteristics and Survival Outcomes of Young Gastric Cancer Patients, Single Center Experience. EJMI 2023;7(3):296–302.
  4. Akyildiz A, Guven DC, Ozluk AA, Ismayilov R, Mutlu E, Unal OU, Yildiz I, Iriagac Y, Turhal S, Akbas S, Bayram E, Telli TA, Turkoz FP, Ozcelik M, Erciyestepe M, Selvi O, Gulbagci B, Erturk I, Isleyen ZS, Kahraman S, Akdag MO, Hamitoglu B, Unek IT, Unal C, Hacibekiroglu İ, Arslan C, Azizy A, Helvaci K, Demirci U, Dizdar O, Basaran M, Goker E, Sendur MA, Yalcin S. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey. Medicine (Baltimore). 2023 Nov 10;102(45):e35950. 
  5. Almuradova E, Seyyar M, Arak H, Tamer F, Kefeli U, Koca S, Sen E, Telli TA, Karatas F, Gokmen I, Turhal NS, Sakalar T, Ayhan M, Ekinci F, Hafizoglu E, Kahraman S, Kesen O, Unal C, Alan O, Celik S, Yekeduz E, Omur O, Gokmen E. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study. Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34749. 
  6. Rukiye Arıkan, Hilal Sağıroğlu Üstün, Nazım Can Demircan, Selver Işık, Tuğba Akın Telli, Alper Yaşar, Abdussamet Çelebi, Nargiz Majidova, Nadiye Sever, Çiğdem Çelikel, Murat Sarı, Özlem Ercelep, Osman Köstek, İbrahim Vedat Bayoğlu. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib. J Oncol Sci. 2023;9(2):53-61.
  7. Ugurlu MU, Bugdayci O, Akmercan A, Kaya H, Akin Telli T, Akoglu H, Gulluoglu BM. Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple? Breast Cancer Res Treat. 2023 Oct;201(3):417-424.
  8. Arikan, R., Atci, M. M., Ay, S., Ayhan, M., Demircan, N. C., Telli, T. A., Çelebi, A., Yaşar, A., Işik, S., Celikel, C., Balvan, O., Bayoglu, I. V., Kostek, O., Dane, F., Yumuk, P. F. Prognostic significance of mucinous histology in leftsided metastatic colorectal cancers with wildtype RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. 
  9. Sinan Koca,  Nalan Akgul Babacan,  Ilker Nihat Okten, Tugba Akin Telli,  Ozkan Ala,  Bilge Aktas Sezen,  Faysal Dane, Perran Fulden Yumuk. The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer. EJMI 2023;7(2):170–174. 
  10. Sinan Koca, Ilker Nihat Okten, Mehmet Besiroglu, Tugba Akin Telli, Ayse Demirci, Mustafa Karaagac, Ahmet Kucukarda, Semiha Urvay, Sedat Tarik Firat, Zeynep Oruc, Mehmet Murat Zerey, Ezgi Coban, Ibrahim Cil, Mahmut Gumus. Where Should Enzalutamide Be in The Metastatic Castration Resistant Prostate Cancer (mCRPC): A Multi-center Study. EJMO 2023;7(1):34–41.
  11. Bregni G, Trevisi E, Saúde Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F. Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review. J Natl Cancer Inst. 2023 May 8; 115(5):505-513. 
  12. Tuğba Başoğlu, Nazım Can Demircan, Rukiye Arıkan, Tugba Akın Telli, Selver Işık, Alper Yasar, Abdussamet Çelebi, Özlem Ercelep, Faysal Dane, Perran Fulden Yumuk.  Comparison of Resected Ampullary and Pancreatic Head Carcinomas: A Single-Center Experience. South. Clin. Ist. Euras. 2022;33(3):326-330. 
  1. Basoglu T, Babacan NA, Ozturk FE, Arikan R, Demircan NC, Telli TA, Ercelep O, Dane F, Yumuk PF. Prognostic value of Gustave Roussy immune score in operable pancreatic adenocarcinoma. Indian J Cancer 2023 Apr-Jun;60(2):179-184.
  2. Özgür G, Çetin M, Telli T, Filinte D, Tinay İ. Testicular Metastasis in Renal Cell Carcinoma. J Urol Surg, 2022;9(4):306-308.
  1.  
  1. Telli TA, Alan O, Demircan NC, Sariyar N, Arikan R, Basoglu T, Yasar A, Celebi A, Isik S, Sofulu O, Erol B, Turkoz HK, Ozgen Z, Ercelep O, Dane F, Yumuk PF. Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities. Orthop Traumatol Surg Res. 2023 May;109(3):103491.
  2. Arikan R, Ozguven S, Telli TA, Isik S, Demircan NC, Basoglu T, Yasar A, Celebi A, Filizoglu N, Ustun HS, Tinay I, Ones T, Turoglu HT, Erdil TY, Ozturk MA, Ercelep O, Bayoglu V, Kostek O, Dane F, Yumuk PF. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters. Acta Radiol. 2023 May;64(5):2040-2049.
  3. Tugba Basoglu, Salih Ozguven, Ceren Ozge Engur, Firat Akagunduz, Nazim Can Demircan, Rukiye Arikan, Fatma Temiz,  Selma Sengun,  Selver Isik,  Tugba Akin Telli,  Abdussamed Celebi, Alper Yasar, Ozlem Ercelep, Faysal Dane, Yumuk, P. F.. Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma. EJMI 2023;7(1):32–41.
  4. Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/ microsatellite stable (MSS) colorectal cancer. Cancer Treat Rev. 2022 Nov;110:102460. 
  5. Nazım Can Demı̇rcan, Ceren Özge Engür, Tuğba Akın Tellı̇, Tuğba Başoğlu, Rukiye Arıkan,  Alper Yaşar,  Abdussamet Çelebı̇,  Özkan Alan,  Selver Işık, Salih Özgüven,  Özlem Ercelep, Faysal Dane, Handan Kaya,  Tunç Öneş, Perran Fulden Yumuk. Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib. Turk J Oncol 2022;37(4):379–87.
  6. Hizal M, Bilgin B, Paksoy N, Atcı MM, Kahraman S, Kılıçkap S, Güven DC, Keskinkılıç M, Ayhan M, Eren Ö, Mustafayev FNA, Yaman Ş, Bayram E, Ertürk İ, Özcan E, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, Baytemür NK, Gülmez A, Aydın D, Şakalar T, Arak H, Tatlı AM, Ergün Y, Ak N, Ünal Ç, Özgün MA, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Şendur MAN. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2023 Jul;149(8):4141-4148.
  7. Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, Isik S, Arikan R, Demircan NC, Basoglu T, Cetin IA, Ones T, Ercelep O, Dane F, Yumuk PF. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. Ann Nucl Med. 2022 Nov;36(11):964-975.
  8. Tugba Basoglu, Nazim Can Demircan, Tugce Kubra Gunes, Mehmet Umut Capar, Merve Cinar, Rukiye Arikan, Tugba Akin Telli, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk. A Laboratory Prognostic Index Model for Predicting Survival in Patients with Malignant Pleural Mesothelioma. EJMI 2022;6(3):352–358.
  9. Telli TA, Ozturk MA, Alan O, Hasanov R, Kostek O, Arikan R, Basoglu T, Kaya S, Ercelep O, Babacan NA, Dane F, Yumuk PF. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. Future Oncol. 2022 Jul;18(22):2425-2439.
  10. Özdemir Ö, Zengel B, Yildiz Y, Oyan Uluç B, Çabuk D, Özden E, Kivrak Salim D, Paydas S, Demir A, Diker Ö, Nur Pilanci K, Uysal Sönmez Ö, Vatansever S, Doğan İ, Gülmez A, Çakar B, Gürsoy P, Emre Yildirim M, Ayhan M, Karadurmuş N, Bariş Aykan M, Tuğba Çevik G, Şakalar T, Hacibekiroğlu İ, Belen Gülbağci B, Dinçer M, Bayir Garbioğlu D, Kemal Y, Nayir E, Taşkaynatan H, Yilmaz M, Avci O, Sari M, Çoban E, Mustafa Atci M, Aktürk Esen S, Akin Telli T, Karataş F, İnal A, Demir H, Önal Kalkan N, Yilmaz C, Taşli F, Alacacioğlu A. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670.
  11. Hizal M, Bilgin B, Paksoy N, Kılıçkap S, Atcı MM, Kahraman S, Keskinkılıç M, Bilgetekin İ, Ayhan M, Tural D, Eren Ö, Akkoç Mustafayev FN, Yaman Ş, Tatlı AM, Bayram E, Kutlu Y, Ertürk İ, Özcan E, Gülmez A, Korkmaz M, Akagündüz B, Erdem D, Telli TA, Aksoy A, Üskent N, İriağaç Y, Baytemür NK, Aydın D, Şakalar T, Arak H, Selçukbiricik F, Ergün Y, Korkmaz T, Ak N, Ünal Ç, Akdeniz N, Özgün MA, Öksüzoğlu B, Yalçın B, Öztop İ, Algın E, Sakin A, Aydıner A, Yumuk PF, Nahit Şendur MA. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582.
  12. Telli TA, Bugdayci O, Alan O, Sariyar N, Isik S, Arikan R, Yasar A, Majidova N, Celebi A, Erol B, Ozgen Z, Kostek O, Bayoglu IV, Ercelep O, Dane F, Yumuk PF. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma. Nutr Cancer. 2022;74(7):2499-2507.
  13. Gursoy P, Tatli AM, Erdem D, Goker E, Celik E, Demirci NS, Sakin A, Atci MM, Bayram E, Telli TA, Bilgin B, Bilici A, Akangunduz B, Balli S, Demirkazik A, Selçukbiricik F, Menekse S, Cavdar E, Ozturk A, Bekmez ET, Turhal S, Kilickap S, Yildirim HÇ, Oyan B, Aksoy A, Turkoz FP, Kut E, Katgi N, Sakalar T, Akyol M, Ellez Hİ, Topcu A, Erdoğan AP, Pilanci KN, Hedem E, Arak H, Akdeniz N, Alan Ö, Yapar B, Nart D, Yumuk PF. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2023 Feb;149(2):865-875.
  14. Akın Telli T, Akgül Babacan N, Alan Ö, Öztürk MA, Hasanov R, Koca S, Halil S, Tanrıkulu Şimşek E, Başoğlu T, Ercelep Ö, Dane F, Yumuk PF. The Prognostic and Predictive Value of DR-70 Immunoassay, A Novel Fibrin-Associated Biomarker, in Patients with Advanced Gastrointestinal Cancers. Nam Kem Med J 2022;10:74-79.
  15. Atci MM, Akagunduz B, Demir M, Dönmez Yılmaz B, Akin Telli T, Can O, Cil İ, Göktaş Aydın S, Ozyurt N, Önder AH, Selvi O, Sakin A. Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated With Concurrent Chemoradiation: A Multicenter Study. Oncol Res Treat. 2022;45(5):254-261. 
  16. Başoğlu T, Akar KE, Bağcı P, Akgül Babacan N, Öztürk MA, Öztürk FE, Demircan NC, Arikan R, Akın Telli T, Ercelep Ö, Dane F, Yumuk PF. Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma. Balkan Med J. 2022 Jan 25;39(1):12-20. 
  17. Nazım Can DEMİRCAN, Tuğba AKIN TELLİ, Tuğba BAŞOĞLU, Alper YAŞAR, Abdussamet ÇELEBİ, Özkan ALAN, Selver IŞIK, Faysal DANE, Perran Fulden YUMUK. Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience. J Oncol Sci. 2021;7(3):133-8.
  18. Baran Akagunduz, Tugba Akin Telli, Hasan Cagri Yıldırım, Sema Sezgin Goksu, Nazan Demır, Emre Hafızoglu, Muhammet Ozer, Gokcen Tugba Cevık, Abdullah Sakın, Sabin Goktas Aydın, Nilay Sengul Samancı, Neslihan Ozyurt, Muhammed Mustafa Atcı, Murat Ayhan, Merve Turan, Nisanur Sarıyar, Cengiz Karacın, Saadettin Kılıckap, Semra Paydas, Mutlu Dogan.  Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group. International Journal of Hematology and Oncology, 2021, 31.2: 092-098.
  19. Başoğlu, T., Özgüven, S., Özkan, H. Ş., Çınar, M., Köstek, O., Demircan, N. C., Arikan, R., Telli, T.A., Ercelep, Ö., Kaya, H., Öneş, T., Erdil, T.Y., Uğurlu, M.Ü., Dane F, Yumuk, P. F. (2021). Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 May-Jun; 41(3):171-178. 
  20. Ali Alkan, Zeynep Gülsüm Güç, Mustafa Gürbüz, Güliz Özgün, Serkan Değirmencioğlu, Mutlu Doğan, Tuğba Akın Telli, Özge Keskin, Çağatay Arslan, Burak Bilgin, Sema Sezgin Göksu, Hacer Demir, Elif Berna Köksoy, Osman Köstek, İsmail Ertürk, Teoman Şakalar, Arzu Yaşar, Görkem Türkkan, Büşra Kasım, Aziz Karaoğlu, Berna Çakmak Öksüzoğlu, Fulden Yumuk, Mehmet Ali Şendur, Hasan Şenol Coşkun, İrfan Çiçin, Nuri Karadurmuş, Özgür Tanrıverdi, Hakan Akbulut, Yüksel Ürün. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients. J. Mens. Health 2021, 17(4), 128-134. 
  21. Tugba Akin Telli, Nisanur Sariyar, Ozkan Alan, Nazim Can Demircan, Selver Isik, Rukiye Arikan, Tugba Basoglu, Alper Yasar, Abdussamet Celebi, Omer Sofulu, Bulent Erol, Huseyin Kemal Turkoz, Zerrin Ozgen, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk. Preoperative Prognostic Nutritional Index is a Strong Predictor of Survival in Patients with Localized Soft Tissue Sarcoma. EJMI 2021;5(2):256–262.  
  22. Arta Fejzullahu, Tugba Akin Telli, Irem Peker Eyuboglu, Perran Fulden Yumuk and Ahmet Ilter Guney. Expression of NF-κB Regulators (BCL-3, NFKB1, NFKB2) in Metastatic Breast Cancer Patients. Cancer Sci Res 4.3 (2021): 1-9.
  23. Rukiye Arikan, Tugba Akin Telli, Ozkan Alan, Nazim Can Demircan, Tugba Basoglu, Ozlem Ercelep, Handan Kaya, Onur Bugdayci, Umit Ugurlu, Zerrin Ozgen, Faysal Dane, Perran Fulden Yumuk. Clinicopathologic and Radiologic Characteristics of Pleomorphic Lobular Breast Cancer. EJMI 2021;5(1):148–152. 
  24. Akagündüz B, Akin Telli T, Sezgin Goksu S, et al. (February 13, 2021) Assessment of Prognostic Factors and Adjuvant Treatment Modalities in Adult Head and Neck Soft Tissue Sarcoma Patients Treated With Upfront Surgery. Cureus. 2021 Feb 13;13(2):e13324. 
  25. Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Sakar M, Bozkurt S, Atasoy BM, Dane F, Ziyal Mİ, Yumuk PF. Impact of prognostic nutritional index on survival in recurrent glioblastoma. Neurocirugia (Astur). 2021 Jan 13:S1130-1473(20)30136-6. English, Spanish. 
  26. Bekir Hacioglu M, Kostek O, Karabulut S, Tastekin D, Sezgin Goksu S, Alandag C, Akagunduz B, Bilgetekin I, Caner B, Bilgehan Sahin A, Yildiz B, Kose F, Kaplan MA, Gulmez A, Dogan E, Can Guven D, Gurbuz M, Ergun Y, Karaagac M, Gokcen Demiray A, Turker S, Sakalar T, Ozkul O, Telli TA, Sahin S, Kilickap S, Bilici A, Erdogan B, Cicin I. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey. J BUON. 2020 Jul-Aug;25(4):1897-1903. 
  27. Arıkan R, Telli TA, Demircan NC, Başoğlu T, Ercelep Ö, Atasoy BM, Özgüven S, Dane F, Yumuk PF. Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature. Curr Probl Cancer. 2021 Apr;45(2):100668. 
  28. Camera S*, Akin Telli T*, Woff E, Vandeputte C, Kehagias P, Guiot T, Critchi G, Wissam Y, Bregni G, Trevisi E, Pretta A, Senti C, Leduc S, Gkolfakis P, Hoerner F, Rothé F, Sclafani F, Flamen P, Deleporte A, Hendlisz A. Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial. Cancers (Basel). 2020 Sep 24;12(10):E2752. (*equal contributor)
  29. Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, Basoglu T, Arikan R, Demircan NC, Ercelep O, Kaya S, Ugurlu MU, Kaya H, Akgul Babacan N, Dane F, Yumuk PF. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? World J Surg Oncol. 2020 Sep 9;18(1):242. 
  30. Ercelep O, Alan O, Telli TA, Tuylu TB, Arıkan R, Demircan NC, Simsek ET, Babacan NA, Kaya S, Dane F, Bozkurtlar E, Ones T, Lacin T, Yumuk PF. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma. Tumori. 2021 Jun; 107(3):231-237. 
  31. Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel. Acta Oncol. 2020 Dec;59(12):1438-1446. 
  32. Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A. MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer. Clin Colorectal Cancer. 2020 Dec;19(4):311-318.e1. 
  33. Ercelep, Ö., Telli, T. A., Alan Ö,, Hasanov, R., Şimşek, E. T., Babacan, N. A., Kaya, S., Kaya, H., Dane, F., Yumuk, P. F. (2020). Smokers having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment? Single-Center Experience. Turk J Oncol 2020;35(3):334–9. 
  34. Akın Telli T,Esin E,Yalçın Ş. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience. Balkan Med J. 2020 Aug 11;37(5):281-286.
  35. Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Bozkurt S, Atasoy BM, Dane F, Yumuk PF. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment. Clin Neurol Neurosurg. 2020 Sep;196:105976. 
  36. Demircan NC, Akın Telli T, Başoğlu Tüylü T, Arıkan R, Kocakaya D, Şahin AA, Ercelep Ö, Dane F, Yumuk PF. QT interval prolongation related to afatinib treatment in a patient with metastatic non-small-cell lung cancer. Curr Probl Cancer. 2020 Dec;44(6):100594.
  37. Basoglu T, Telli TA, Demircan NC, Arikan R, Ercelep O, Ozguven S, Soysal S, Memisoglu A, Dane F, Yumuk PF. A rare case of gastric cancer with bilateral breast metastasis during pregnancy. J Oncol Pharm Pract. 2021 Jan;27(1):220-226.
  38. Alan O, Telli TA, Tuylu TB, Arikan R, Demircan NC, Ercelep O, Kaya S, Babacan NA, Atasoy BM, Bozkurt S, Bayri Y, Gul D, Ekinci G, Ziyal I, Dane F, Yumuk PF. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience. J Oncol Pharm Pract. 2021 Mar;27(2):329-339.
  39. Demirelli B, Babacan NA, Ercelep Ö, Öztürk MA, Kaya S, Tanrıkulu E, Khalil S, Hasanov R, Alan Ö, Telli TA, Koca S, Arıbal ME, Kuzan B, Dane F, Yumuk PF. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutr Cancer. 2021;73(2):230-238.
  40. Ercelep, O., Alan, O., Telli, T. A., Tuylu, T. B., Arikan, R., Demircan, N. C., Kocakaya, D., Dane, F., Lacin, T., Bozkurtlar, E., Yumuk, P. F. Comparison of Seventh and Eighth Editions of TNM Staging Classification and Evaluation of Survivals in Operated Non-Small Cell Lung Carcinomas: Single Center Experience. EJMI 2020;4(2):243-246.
  41.  
  42. Telli TA, Okten IN, Tuylu TB, Demircan NC, Arikan R, Alan O, Ercelep O, Ones T, Yildirim AT, Dane F, Yumuk PF. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature. Curr Probl Cancer. 2020 Oct;44(5):100568.
  43. Akkiprik M, Koca S, Uğurlu MÜ, Ekren R, Peker Eyüboğlu İ, Alan Ö, Erzik C, Güllü Amuran G, Telli TA, Güllüoğlu MB, Sezerman U, Yumuk PF. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy. Clin Breast Cancer. 2020 Aug;20(4):332-343.e3.
  44. Bregni, G., Akin Telli, T., Camera, S., Deleporte, A., Moretti, L., Bali, A.M., Liberale, G., Holbrechts, S., Hendlisz, A., Sclafani, F. Adjuvant chemotherapy for rectal cancer: current evidence and recommendations for clinical practice. Cancer Treat Rev. 2020 Feb;83:101948.
  45. Kuzan TY, Kuzan BN, Telli TA, Tüney D. Evaluation of the frequency of left renal vein variations in computed tomography and its relationship with cancer development. Folia Morphol (Warsz). 2020;79(4):793-798.
  46. Demircan NC, Alan Ö, Başoğlu Tüylü T, Akın Telli T, Arıkan R, Çiçek FC, Ercelep Ö, Öztürk MA, Alsan Çetin İ, Ergelen R, Tinay İ, Akgül Babacan N, Kaya S,Dane F, Yumuk PF. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib. J Oncol Pharm Pract. 2020 Jul;26(5):1147-1155.
  47. Bregni G, Akin Telli T, Camera S, Baratelli C, Shaza L, Deleporte A, Moretti L, Bali MA, Liberale G, Hendlisz A, Sclafani F. Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines. Cancer Treat Rev. 2020 Jan;82:101930.
  48. Telli TA, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F. PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Lett. 2020 Jan 28; 469:142-150. 
  49. Alan O, Kuzhan O, Koca S, Telli TA, Tuylu TB, Ercelep O, Filinte D, Sengul Y,  Arikan H, Kaya S, Babacan NA, Dane F, Yumuk PF. How long should we continue
  50. crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature. J Oncol Pharm Pract. 2020 Jun;26(4):1011-1018.
  51. Telli TA, Demircan NC, Alan O, Tuylu TB, Arikan R, Ercelep O, Atıcı AE, Ergelen R, Seven IE, Babacan NA, Kaya S, Dane F, Fulden Yumuk P. A rare case of primary rectal choriocarcinoma and review of the literature. J Oncol Pharm Pract.
  52.            2020 Jun;26(4):989-994.
  53.  
  54. Kıvrak Salim D, Akın Telli T, Tatlı AM, Kılıçkap S, Yumuk PF. Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients. Cancer Chemother Pharmacol. 2019 Jun;83(6):1137-1145. 
  55. Ercelep O, Alan O, Sahin D, Telli TA, Salva H, Tuylu TB, Babacan NA, Kaya S, Dane F, Ones T, Alkis H, Adli M, Yumuk F. Effect of PET/CT standardized uptake values on complet response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Clin Transl Oncol. 2019 Apr;21(4):499-504.
  56. Alan O, Akin Telli T, Ercelep O, Tanrikulu Simsek E, Basoglu Tuylu T, Mutis A, Hasanov R, Kaya S, Akgül Babacan N, Dane F, Yumuk PF. Chordoma: a case series and review of the literature. J Med Case Rep. 2018 Aug 27;12(1):239.
  57. Alan O, Telli TA, Ercelep O, Hasanov R, Simsek ET, Mutis A, Ones T, Kaya H, Yumuk PF. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. Curr Probl Cancer. 2019 Aug;43(4):308-311.
  58. Gunes A, Karakus MF, Telli TA, Gunes NA, Mutlu M. The effect of thyroid autoantibody positivity on the functions of internal ear. Eur Arch Otorhinolaryngol. 2017 Nov;274(11):3853-3858.
  59. Esin E, Akin Telli T, Yuce D, Yalcin S. A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity. Tumori. 2018 Jun; 104(3):157-164.
  60. Telli O, Sarici H, Ekici M, Ozgur BC, Doluoglu OG, Eroglu M, Telli TA. Does metabolic syndrome or its components associate with prostate cancer when diagnosed on biopsy? Ther Adv Med Oncol. 2015 Mar;7(2):63-7.
  61. Karadag O, Akin T, Ertenli AI. An unusual clinical presentation of amyloidosis: auricular concha involvement. J Rheumatol. 2014 Jan;41(1):140.
  62. I.Petekkaya, T. Akin, G. Gezgen, E.C. Roach, Y. Ozisik, K. Altundag. Electrolyte abnormalities due to irinotecan administration in metastatic HER-2 positive breast cancer patients. J BUON. 2012 Oct-Dec;17(4):800.